Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer

NCT06644170 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06644170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06644170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
November 19, 2024
Completion date
September 30, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphatic system neoplasm, metastatic malignant solid neoplasm